Antidiabetic Pharmacology Part 2 - Injectables

Injectable medications play a central role in the management of Type II Diabetes Mellitus (T2DM), particularly for patients who are unable to achieve glycemic control through lifestyle modifications and oral agents alone. This 1-hour CME/CE course offers a comprehensive introduction to injectable antidiabetic therapies, focusing on their pharmacological mechanisms, clinical indications, side effects, and contraindications.

The program begins by reviewing the current classification, diagnosis, and screening practices for type 2 diabetes mellitus (T2DM). It then presents glycemic targets aligned with ADA guidelines and explores the role of injectable medications such as insulin (basal, prandial, premixed) and GLP-1 receptor agonists. Emphasis is placed on safe prescribing practices, titration protocols, and patient-centered care to minimize adverse events and optimize outcomes.

This course fulfills pharmacology education requirements for physicians, nurses, and physician assistants across multiple states, including Massachusetts, Ohio, Rhode Island, Mississippi, Maryland, Hawaii, and the District of Columbia.

Educational Objectives

• Cite the prevalence, screening criteria, classification, and diagnosis of Type II Diabetes Mellitus.
• Identify target glycemic goals based on established clinical guidelines for T2DM management.
• Discuss the clinical indications, dosing protocols, pharmacology, side effects, and contraindications of injectable medications used in T2DM treatment.

Who Should Take This Course

This course is recommended for:

• Physicians, Physician Assistants, and Nurses fulfilling pharmacology CE requirements in Massachusetts, Ohio, Rhode Island, Maryland, Hawaii, Mississippi, and the District of Columbia.
• Endocrinologists, primary care providers, and diabetes educators are involved in the management of Type II Diabetes.
• Clinicians looking to enhance their understanding of insulin therapy, GLP-1 receptor agonists, and advanced injectable options.
• Providers focused on minimizing hypoglycemia risk and personalizing care through evidence-based injectable pharmacotherapy.

Did You Know?

• Over 10% of U.S. adults have diabetes, and nearly 90–95% of them have Type II Diabetes. [CDC, 2022]
• GLP-1 receptor agonists not only lower blood sugar but also promote weight loss and cardiovascular protection. [NEJM, 2021]
• Insulin remains the most effective agent for achieving glycemic control in severe hyperglycemia. [ADA Guidelines, 2023]
• The risk of hypoglycemia varies significantly among different insulin formulations and dosing schedules.
• Patient education and regular follow-up are key components in the success of injectable diabetes therapies.